Addition of Salmeterol versus Doubling the Dose of Beclomethasone in Children with Asthma
| Autor: | Verberne, AAPH, Frost, C, Duiverman, EJ, Grol, MH, Kerrebijn, KF, Raaymakers, JAM, Pocock, SJ, Bogaard, JM, van Nierop, Jacobus, Nagelkerke, AF, Thio, B, van Essen-Zandvliet, EEM, Denteneer, A, Gerritsen, J, Grol, MJ, Hendriks, JJE, Kouwenberg, JM, van der Laag, J, Brackel, HJL |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Pulmonary and Respiratory Medicine
SYMPTOMS AIRWAY medicine.drug_class INHALED CORTICOSTEROIDS Critical Care and Intensive Care Medicine Placebo Bronchodilator medicine SALBUTAMOL LONG-TERM TREATMENT STATEMENT business.industry BRONCHIAL RESPONSIVENESS CHILDHOOD ASTHMA Beclometasone dipropionate respiratory system Effective dose (pharmacology) respiratory tract diseases LUNG-FUNCTION Anesthesia Salbutamol GROWTH Corticosteroid Methacholine Salmeterol business medicine.drug |
| Zdroj: | American Journal of Respiratory and Critical Care Medicine, 158(1), 213-219. AMER THORACIC SOC |
| ISSN: | 1535-4970 1073-449X |
| DOI: | 10.1164/ajrccm.158.1.9706048 |
| Popis: | Studies in adults revealed that addition of salmeterol to a moderate dose of inhaled corticosteroid resulted in better symptom control and higher PEF compared with doubling the dose of inhaled corticosteroid. The aim of this three group study was to compare the effects of a moderate dose of beclomethasone, the same dose of beclomethasone with salmeterol, and a doubling dose of beclomethasone on lung function and symptoms in children with moderate asthma. A total of 177 children already treated with inhaled corticosteroids, were randomized in a double-blind parallel study either to salmeterol 50 microg twice daily (BDP400+salm), beclomethasone 200 microg twice daily (BDP800), or placebo (BDP400) in addition to beclomethasone 200 microg twice daily. No significant differences between groups were found in FEV1, PD20 methacholine, symptom scores, and exacerbation rates after 1 yr. Salmeterol resulted in slightly better PEF in the first months of treatment. FEV1, and PD20 methacholine significantly improved in all groups. After 1 yr mean changes in FEV1, percent predicted were 4.3% (95% CI 1.3; 7.2), 5.8% (95% CI 2.9; 8.7), and 4.3% (95% CI 2.1; 6.5) for BDP400+salm, BDP800, and BDP400, respectively. Changes in airway responsiveness were 0.60 (95% CI 0.05; 1.14), 1.30 (95% CI 0.73; 1. 87), and 0.80 (95% CI 0.33; 1.27) doubling doses. Growth was significantly slower in the BDP800 group. We conclude that no additional benefit was found of adding either salmeterol or more beclomethasone to a daily dose of 400 microg beclomethasone in this group of children with excellent compliance of medication. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|